p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.

p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.

The KIT-inhibitor imatinib mesylate (IM) has greatly improved the treatment of metastatic gastrointestinal stromal tumors (GIST). IM exhibits strong antiproliferative effects but fails to induce sufficient levels of apoptosis resulting in low pathologic complete remission rates and a high rate of se...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Joern Henze, Thomas Mühlenberg, Susanne Simon, Florian Grabellus, Brian Rubin, Georg Taeger, Martin Schuler, Juergen Treckmann, Maria Debiec-Rychter, Takahiro Taguchi, Jonathan A Fletcher, Sebastian Bauer
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2012
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/eb08851ab2234325acf4d31cce831a44
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/eb08851ab2234325acf4d31cce831a44

Ejemplares similares